|
EP1737890A2
(en)
|
2004-03-24 |
2007-01-03 |
Xencor, Inc. |
Immunoglobulin variants outside the fc region
|
|
EP2471813B1
(en)
|
2004-07-15 |
2014-12-31 |
Xencor, Inc. |
Optimized Fc variants
|
|
US8802820B2
(en)
|
2004-11-12 |
2014-08-12 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
AU2005304624B2
(en)
|
2004-11-12 |
2010-10-07 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
US7855279B2
(en)
|
2005-09-27 |
2010-12-21 |
Amunix Operating, Inc. |
Unstructured recombinant polymers and uses thereof
|
|
HRP20150279T1
(en)
|
2007-12-26 |
2015-05-08 |
Xencor, Inc. |
Fc variants with altered binding to fcrn
|
|
US8278988B2
(en)
|
2008-06-27 |
2012-10-02 |
Freescale Semiconductor, Inc. |
Method and apparatus for generating a modulated waveform signal
|
|
ES2610356T3
(en)
|
2009-02-03 |
2017-04-27 |
Amunix Operating Inc. |
Extended recombinant polypeptides and compositions comprising the same
|
|
KR101813727B1
(en)
|
2009-06-08 |
2018-01-02 |
아뮤닉스 오퍼레이팅 인코포레이티드 |
Growth hormone polypeptides and methods of making and using same
|
|
WO2010144508A1
(en)
|
2009-06-08 |
2010-12-16 |
Amunix Operating Inc. |
Glucose-regulating polypeptides and methods of making and using same
|
|
CA2771999A1
(en)
|
2009-08-24 |
2011-03-10 |
Amunix Operating Inc. |
Coagulation factor vii compositions and methods of making and using same
|
|
ES2993140T3
(en)
|
2010-04-02 |
2024-12-23 |
Amunix Pharmaceuticals Inc |
Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
|
|
WO2013096948A1
(en)
|
2011-12-23 |
2013-06-27 |
Lydon Nicholas B |
Immunoglobulins and variants directed against pathogenic microbes
|
|
US9988439B2
(en)
|
2011-12-23 |
2018-06-05 |
Nicholas B. Lydon |
Immunoglobulins and variants directed against pathogenic microbes
|
|
EP2822577B1
(en)
|
2012-02-15 |
2019-02-06 |
Bioverativ Therapeutics Inc. |
Recombinant factor viii proteins
|
|
JP6256882B2
(en)
|
2012-02-15 |
2018-01-10 |
アムニクス オペレーティング インコーポレイテッド |
Factor VIII composition, and method of making and use of the composition
|
|
JP6355563B2
(en)
|
2012-02-27 |
2018-07-11 |
アムニクス オペレーティング インコーポレイテッド |
XTEN conjugate composition and method for producing the same
|
|
CN104519903A
(en)
|
2012-06-05 |
2015-04-15 |
阿穆尼克斯运营公司 |
HGH-XTEN fusion protein and its use in the treatment of growth hormone deficiency
|
|
TW202003554A
(en)
|
2013-08-14 |
2020-01-16 |
美商百歐維拉提夫治療公司 |
Factor VIII-XTEN fusions and uses thereof
|
|
CN109293782A
(en)
|
2014-01-08 |
2019-02-01 |
德益阳光生物技术(北京)有限责任公司 |
Fused polypeptide and application method
|
|
EP3200823B1
(en)
|
2014-10-02 |
2022-11-23 |
City of Hope |
Multivalent meditopes, meditope-binding antibodies and uses thereof
|
|
WO2017008758A1
(en)
|
2015-07-15 |
2017-01-19 |
Prosit Sole Biotechnology (Beijing) Co., Ltd |
Fusion polypeptides and methods of use
|
|
EA201890423A1
(en)
|
2015-08-03 |
2018-07-31 |
Биовератив Терапьютикс Инк. |
SLIGHT PROTEINS OF THE FACTOR IX, METHODS OF THEIR RECEPTION AND APPLICATION
|
|
MX2019006444A
(en)
|
2016-12-02 |
2019-10-30 |
Bioverativ Therapeutics Inc |
HEMOPHILIC ARTHROPATHY TREATMENT METHODS USING CHEMERIC COAGULATION FACTORS.
|
|
PL3793588T3
(en)
|
2018-05-18 |
2025-09-01 |
Bioverativ Therapeutics Inc. |
Methods of treating hemophilia a
|
|
JP7725466B2
(en)
|
2019-11-13 |
2025-08-19 |
アムニクス ファーマシューティカルズ, インコーポレイテッド |
Barcoded XTEN polypeptides and compositions thereof, and methods of making and using same
|
|
KR20230041711A
(en)
|
2020-06-25 |
2023-03-24 |
아뮤닉스 파마슈티컬스, 인크. |
HER-2 targeting bispecific compositions and methods of making and using the same
|
|
KR20250133776A
(en)
|
2023-02-10 |
2025-09-08 |
아뮤닉스 파마슈티컬스, 인크. |
Composition targeting prostate-specific membrane antigen (PSMA) and methods for preparing and using the same
|
|
CN121949565A
(en)
|
2023-04-17 |
2026-05-01 |
阿穆尼克斯制药公司 |
Compositions targeting epidermal growth factor receptors, their preparation and application methods
|
|
WO2025122957A1
(en)
|
2023-12-08 |
2025-06-12 |
Amunix Pharmaceuticals, Inc. |
Protease activatable cytokines and methods for making and using the same
|
|
WO2026024863A2
(en)
|
2024-07-24 |
2026-01-29 |
Amunix Pharmaceuticals, Inc. |
Compositions targeting prostate-specific membrane antigen (psma) in combination with androgen receptor antagonists
|